BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 27074923)

  • 1. CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.
    Zong G; Xu Z; Zhang S; Shen Y; Qiu H; Zhu G; He S; Tao T; Chen X
    Dig Dis Sci; 2016 Aug; 61(8):2303-2314. PubMed ID: 27074923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
    Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
    Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma.
    Qiu H; Zhang X; Ni W; Shi W; Fan H; Xu J; Chen Y; Ni R; Tao T
    Dig Dis Sci; 2016 Mar; 61(3):795-805. PubMed ID: 26553251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.
    Zhang T; Wan C; Shi W; Xu J; Fan H; Zhang S; Lin Z; Ni R; Zhang X
    J Mol Histol; 2015 Dec; 46(6):485-97. PubMed ID: 26438629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
    Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
    PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma.
    Bi JG; Zheng JF; Li Q; Bao SY; Yu XF; Xu P; Liao CX
    Int J Biochem Cell Biol; 2019 Jan; 106():107-116. PubMed ID: 30503931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.
    Rong M; Chen G; Dang Y
    BMC Cancer; 2013 Jan; 13():21. PubMed ID: 23320393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.
    Wang W; Jia WD; Hu B; Pan YY
    Oncotarget; 2017 Apr; 8(16):26434-26447. PubMed ID: 28460436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma.
    Ye BG; Sun HC; Zhu XD; Chai ZT; Zhang YY; Ao JY; Cai H; Ma DN; Wang CH; Qin CD; Gao DM; Tang ZY
    Oncotarget; 2016 May; 7(20):29333-45. PubMed ID: 27121053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
    Tian F; Cai D
    Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The zinc finger protein GATA4 induces mesenchymal-to-epithelial transition and cellular senescence through the nuclear factor-κB pathway in hepatocellular carcinoma.
    Xiang Q; Zhou D; He X; Fan J; Tang J; Qiu Z; Zhang Y; Qiu J; Xu Y; Lai G
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2196-2205. PubMed ID: 30995348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation.
    Chen HW; Huang XD; Li HC; He S; Ni RZ; Chen CH; Peng C; Wu G; Wang GH; Wang YY; Zhao YH; Zhang YX; Shen AG; Wang HM
    Mol Carcinog; 2013 Aug; 52(8):647-59. PubMed ID: 22488567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentivirus-mediated shRNA Targeting CNN2 Inhibits Hepatocarcinoma
    Kang X; Wang F; Lan X; Li X; Zheng S; Lv Z; Zhuang Y; Zhao Y; Zhou S
    Int J Med Sci; 2018; 15(1):69-76. PubMed ID: 29333089
    [No Abstract]   [Full Text] [Related]  

  • 19. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
    Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
    Zhu J; Huang S; Wu G; Huang C; Li X; Chen Z; Zhao L; Zhao Y
    Dig Dis Sci; 2015 Oct; 60(10):3019-31. PubMed ID: 26048020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.